KD019 Versus Erlotinib in Subjects With Stage IIIB/IV Non Small Cell Lung Cancer With Progression After First- or Second-Line Chemotherapy

PHASE3

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped Kadmon has made a business decision to terminate the study due to slow enrollment. Note the decision to terminate the study was not related to safety issues

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG: KD019
DRUG: Erlotinib

Sponsor

Kadmon Corporation, LLC